Hepatic steatosis-insulin resistance and type 2 diabetes in people with HIV at diagnosis: effect of initial antiretroviral therapy
- PMID: 39474653
- DOI: 10.1097/QAD.0000000000004008
Hepatic steatosis-insulin resistance and type 2 diabetes in people with HIV at diagnosis: effect of initial antiretroviral therapy
Abstract
We evaluated the impact of hepatic steatosis-insulin resistance (HS-IR) and liver fibrosis (LF) on type 2 diabetes mellitus (DM2) using triglyceride-glucose (TyG) and Fibrosis-4 (FIB-4). The incidence of DM2 was 12.9 [95% confidence interval (CI), 16.9-9.7] and 9.8 (95% CI, 6.9-13.6) per 1000 person-years in HS-IR and LF. The prevalence of HS-IR was significantly lower at 12 and 24 months with TDF + (3TC or FTC) + RPV [hazard ratio (HR) 0.5 [95% CI, 0.3-0.8], P < 0.01 at 12 months; 0.6 [0.4-0.9], P = 0.01 at 24 months].
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
References
-
- Sarkar S, Brown TT. Diabetes in people with HIV . Curr Diab Rep 2021; 21:13.
-
- Sudipa Sarkar TTB. DM in PLWHIV . Curr Diab Rep 2022; 21:1–13.
-
- Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2 diabetes and its impact on the immune system . Curr Diabetes Rev 2020; 16:442–449.
-
- Gutiérrez-Fisac JL, Guallar-Castillón P, León-Muñoz LM, Graciani A, Banegas JR, Rodríguez-Artalejo F. Prevalence of general and abdominal obesity in the adult population of Spain, 2008–2010: the ENRICA study . Obes Rev 2012; 13:388–392.
-
- Monroe AK, Glesby MJ, Brown TT. Diagnosing and managing diabetes in HIV-infected patients: current concepts . Clin Infect Dis 2015; 60:453–462.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
